Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Myriad Genetics, Inc. shares valued at $321,019 were purchased by Ancona Margaret on Aug 21 ’24. At $27.82 per share, Ancona Margaret acquired 11,538 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, DIAZ PAUL J sold 15,000 shares, netting a total of over 400,800 in proceeds. Following the sale of shares at $26.72 each, the insider now holds 977,378 shares.
Before that, Muzzey Dale had sold 2,100 shares from its account. In a trade valued at $54,961, the Chief Scientific Officer traded Myriad Genetics, Inc. shares for $26.17 each. Upon closing the transaction, the insider’s holdings decreased to 2,100 shares, worth approximately $2.83 million.
As published in their initiating research note from Morgan Stanley on September 19, 2024, Myriad Genetics, Inc. [MYGN] has been an Equal-weight and the price target has been revised to $32. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in late August. As of June 27, 2024, Scotiabank has initiated its “Sector outperform” rating for MYGN.
Analyzing MYGN Stock Performance
During the last five days, there has been a drop of approximately -7.28%. Over the course of the year, Myriad Genetics, Inc. shares have jumped approximately 37.04%. Shares of the company reached a 52-week high of $29.30 on 09/18/24 and a 52-week low of $17.18 on 01/08/24. A 50-day SMA is recorded $27.42, while a 200-day SMA reached $23.28. Nevertheless, trading volume fell to 0.62 million shares from 0.56 million shares the previous day.
Support And Resistance Levels for Myriad Genetics, Inc. (MYGN)
According to the 24-hour chart, there is a support level at 25.82, which, if violated, would cause prices to drop to 25.42. In the upper region, resistance lies at 26.71. The next price resistance is at 27.19. RSI (Relative Strength Index) is 42.43 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.93, which suggests the price will decrease in the coming days. Percent R is at 79.95%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.